Allogene Therapeutics Inc.

25.66-1.98-7.16%Vol 749.37K1Y Perf -26.25%
Sep 24th, 2021 16:00 DELAYED
BID25.65 ASK25.69
Open27.51 Previous Close27.64
Pre-Market- After-Market-
 - -  - -%
Target Price
44.73 
Analyst Rating
Moderate Buy 1.63
Potential %
74.32 
Finscreener Ranking
★★★+ —    -
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★+     57.76
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★ —    -
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
20.87 
Earnings Rating
Buy
Market Cap3.65B 
Earnings Date
3rd Nov 2021
Alpha-0.00 Standard Deviation0.20
Beta1.08 

Today's Price Range

25.5627.64

52W Range

20.5844.92

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
1.10%
1 Month
6.34%
3 Months
6.12%
6 Months
-25.58%
1 Year
-26.25%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ALLO25.66-1.9800-7.16
AAPL146.920.09000.06
GOOG2 852.6616.13000.57
MSFT299.35-0.2100-0.07
XOM57.590.51000.89
WFC47.920.12000.25
JNJ164.36-0.5000-0.30
FB352.967.00002.02
GE103.800.84000.82
JPM163.041.86001.15
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.55-0.533.64
Q01 2021-0.48-0.2547.92
Q04 2020-0.56-0.535.36
Q03 2020-0.55-0.525.45
Q02 2020-0.55-0.533.64
Q01 2020-0.57-0.5012.28
Q04 2019-0.69-0.5815.94
Q03 2019-0.54-0.507.41
Earnings Per EndEstimateRevision %Trend
9/2021 QR-0.553.51Positive
12/2021 QR-0.575.00Positive
12/2021 FY-1.875.56Positive
12/2022 FY-2.462.77Positive
Next Report Date3rd Nov 2021
Estimated EPS Next Report-0.55
Estimates Count12
EPS Growth Next 5 Years %-
Volume Overview
Volume749.37K
Shares Outstanding142.18M
Shares Float87.20M
Trades Count10.29K
Dollar Volume19.42M
Avg. Volume983.15K
Avg. Weekly Volume851.30K
Avg. Monthly Volume665.34K
Avg. Quarterly Volume813.02K

Allogene Therapeutics Inc. (NASDAQ: ALLO) stock closed at 25.66 per share at the end of the most recent trading day (a -7.16% change compared to the prior day closing price) with a volume of 749.67K shares and market capitalization of 3.65B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 265 people. Allogene Therapeutics Inc. CEO is David D. Chang.

The one-year performance of Allogene Therapeutics Inc. stock is -26.25%, while year-to-date (YTD) performance is 1.66%. ALLO stock has a five-year performance of %. Its 52-week range is between 20.58 and 44.92, which gives ALLO stock a 52-week price range ratio of 20.87%

Allogene Therapeutics Inc. currently has a PE ratio of -13.90, a price-to-book (PB) ratio of 3.52, a price-to-sale (PS) ratio of 92.15, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -20.02%, a ROC of -21.26% and a ROE of -21.83%. The company’s profit margin is -%, its EBITDA margin is -588.90%, and its revenue ttm is $38.39 Million , which makes it $0.27 revenue per share.

Of the last four earnings reports from Allogene Therapeutics Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.55 for the next earnings report. Allogene Therapeutics Inc.’s next earnings report date is 03rd Nov 2021.

The consensus rating of Wall Street analysts for Allogene Therapeutics Inc. is Moderate Buy (1.63), with a target price of $44.73, which is +74.32% compared to the current price. The earnings rating for Allogene Therapeutics Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Allogene Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Allogene Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 11.55, ATR14 : 1.22, CCI20 : 141.86, Chaikin Money Flow : 0.12, MACD : 0.66, Money Flow Index : 67.43, ROC : 2.03, RSI : 55.09, STOCH (14,3) : 44.44, STOCH RSI : 0.13, UO : 55.00, Williams %R : -55.56), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Allogene Therapeutics Inc. in the last 12-months were: Alison Moore (Option Excercise at a value of $240 148), Alison Moore (Sold 130 576 shares of value $5 326 671 ), Arie S. Belldegrun (Option Excercise at a value of $6 906 582), David D. Chang (Option Excercise at a value of $499 410), David D. Chang (Sold 20 513 shares of value $791 271 ), Eric Schmidt (Option Excercise at a value of $271 423), Eric Schmidt (Sold 68 053 shares of value $2 353 897 ), Owen N. Witte (Sold 19 969 shares of value $493 623 ), Rafael Amado (Sold 19 336 shares of value $757 985 ), Veer Bhavnagri (Option Excercise at a value of $253 105), Veer Bhavnagri (Sold 66 623 shares of value $2 105 983 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
11 (68.75 %)
10 (62.50 %)
9 (60.00 %)
Moderate Buy
0 (0.00 %)
1 (6.25 %)
1 (6.67 %)
Hold
5 (31.25 %)
5 (31.25 %)
5 (33.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.63
Moderate Buy
1.69
Moderate Buy
1.73

Allogene Therapeutics Inc.

Allogene Therapeutics Inc is the United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.

CEO: David D. Chang

Telephone: +1 650 457-2700

Address: 210 East Grand Avenue, South San Francisco 94080, CA, US

Number of employees: 265

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

100%0%

Bearish Bullish

64%36%

Bearish Bullish

64%36%

News

Stocktwits